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ABSTRACT
We present a case of of young 27year male who was admitted with history of headache and vomiting for one week. 
He was diagnosed as having dural sinus thrombosis of superior sagittal, right lateral, right sigmoid sinus. There was 
previous history of uveitis 6 months prior to it. All thrombophilia workup was negative except homocysteine levels were 
moderately high. He was also found to be having recurring genital and oral ulcers. Pathergy test was negative. His HLA 
B 51/5 testing came back positive. Final diagnosis of Bechet’s disease was made and responded well to long term 
steroids and Colchicine. A multisystem vasculitis like Bechet’s disease should always be thought in patients with 
venous thrombosis with negative thrombophilia screening and recurrent oral and genital ulcers.
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C A S E  R E P O R T
INTRODUCTION:
Behçet disease (BD) is a rare vasculitic disorder that is 
characterized by a triple-symptom complex of recurrent 
oral aphthous ulcers, genital ulcers, and 
uveitis.1Neurologic manifestations (neuro-BD) are 
relatively rare2. The frequency of neurologic 
manifestations varies, ranging from 5% to 30% of 
patients. CVT represents approximately 30% of all CNS 
lesions of BD2.
Case report
A 27 years old male was admitted with history of 
headache for last one week which was gradual onset, 
severe and generalised. Headache was associated with 
multiple episodes of vomiting. There was vague history 
of low grade fever on and off for last 20 days. No history 
of fits or loss of consciousness. There was previous 
history of visual impairment and redness left eye about 
a year ago and was diagnosed as having uveitis and 
macular edema and treated with topical and intraocular 
steroids. There was history of testicular swelling couple 
of months ago which resolved with anti-inflammatory 
and antibiotics. There was history of recurrent oral and 
genital ulcers and multiple OPD visits with them.
At presentation his GCS was 15/15. He had a pulse of 
82/minute, regular, temperature of 99F.There were no 
signs were meningeal irritation. Motor and sensory 
system examination was normal. His initial CT scan 
brain was normal. Blood cultures were negative. His 
ESR was 70mm and CRP was 17. CSF R/E showed 15 
cells, out of which 60% were neutrophils. CSF proteins 
were 28mg/dl. CSF glucose was 55mg/dl. He was 
started on Injection ceftriaxone 2gmIV BD along with 
vancomycin. However, he did not improve, headache 
did not settle. On 7th post admission day he developed 
diplopia right lateral gaze and severe headache with 
vomiting. His MRI brain showed cerebral venous 
thrombosis involving superior sagittal, right lateral, right 
sigmoid and confluence of sinuses. There was partial 
thrombosis of left lateral sinus as well.
He was started on LMWH along with antibiotics were 
switched to meropenum in meningitic dose. Meanwhile 
he was also worked up for Brucella, HIV, syphilis. HIV 
serology was negative. Brucella antibodies were 
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negative. VDRL/RPR serology was also negative. During 
hospital he again developed oral ulcers along with 
scrotal ulcers with cervical and inguinal 
lymphadenopathy. Lymph node biopsy was not possible 
as size of lymph nodes was very small.
His thrombophilia screening also came back negative 
except serum homocysteine levels which were 
moderately high (22.8, desirable< 15umol/L). His 
vasculitis screen including ANA, Anti DsDNA, 
anticardiolipin antibodies and anti ENA antibodies were 
negative. Pathergy test on him was negative. After six 
months of anticoagulation MRV was repeated which 
revealed partial recanalization of right transverse and 
sigmoid sinus, rest of the MRV findings were 
unchanged. 
Few months later he again presented with high grade 
intermittent fever, not responding to antibiotics. Blood 
cultures were negative. CRP was 82mg/L, ESR was 
110mm . All workup for fever was repeated but no 
source was found. Patient was put on steroids and 
fever settled
His HLA B 51/5 testing was also done which came back 
positive.
Our patient satisfied the International Study Group 
criteria for the diagnosis of Behcet’s disease (table 1)3. 
He was also started on colchicine thinking of Behcet 
disease.
Discussion
Behçet’s disease is a multisystem inflammatory 
condition most commonly seen in those of 
Mediterranean and Eastern origin4. It is observed 
commonly among populations living along the historic 
Silk Road5. The exact cause is unknown. However, 
combination of genetic and environmental factors is 
likely to play a role5
Neurologic manifestations (neuro-BD) are relatively 
rare, but they must be thoroughly investigated due to 
their severe prognosis2 
Vascular involvement is not limited to any vessel size, 
affects veins more than arteries and, when present, 
can be associated with constitutional symptoms. 
Patients might develop venous thrombosis affecting the 
lower limbs, vena cava or hepatic veins. Occasionally, 
haemoptysis as a result of pulmonary artery aneurysms 
occurs, and is associated with worse outcomes4. 
Behçet disease is most common in persons aged 
20-40 years. The mean age at onset is 25-30 years. 
Cases that develop before age 25 years are more likely 
to involve eye disease and active clinical disease6.
The characteristic ocular feature is relapsing uveitis as 
anterior, posterior, or panuveitis, and retinal vasculitis. 
Venous sinus thrombosis is the most frequent vascular 
manifestation in nonparenchymal disease followed by 
cortical cerebral veins thrombosis6.
Orchitis and epididymitis can also occur in patients with 
BD6
Saadoun et al found that cerebral venous thrombosis 
(CVT) was present in 7.8% of a large cohort of patients 
with Behçet disease. The main complication of CVT was 
severe visual loss due to optic atrophy. Papilledema 
and concurrent prothrombotic risk factors were 
independently associated with the occurrence of 
sequelae; peripheral venous thrombosis and 
concurrent prothrombotic risk factors were associated 
with relapse of thrombosis. Anticoagulant therapy 
proved safe and effective in up to 90% of patients2 
However, there are controversial recommendations 
about anticoagulation. According to EULAR 
recommenations, beneficial role of anticoagulation is 
unclear, and can lead to adverse events in patients with 
coexistent pulmonary aneurysms7. We however treated 
our patients with anticoagulation for one year and he 
tolerated it well with no complication.
Hyperhomocysteinemia was found in up to 12% of 
patients2. Hyperhomocysteinenmia was found in our 
patient as concomitant prothrombotic risk factor and 
was appropriately treated.
Venous thrombosis in Behçet’s disease is caused by 
phlebitis and not thrombophilia: hence the thrombus 
remains attached to the inflamed vessel wall and tends 
not to metastasise. Venous thrombosis responds well 
to treatment with immunosuppression8.
The first-line treatment for mucocutaneous 
manifestation of Behcet's Disease is colchicine (1 
mg/day)5. Immunosuppressive therapy may cause 
overwhelming infections and patients should be 
counselled about this before the initiation of treatment
 This case emphasizes the importance of identifying the 
cause of unprovoked venous thromboses and that 
clinicians should consider Behçet’s disease in 
appropriate ethnic groups, particularly in patients with a 
history of recurrent oral or genital ulceration. Increasing 
V O L .  1 3  ( 2 )   A P R I L - J U N E  2 0 1 8
awareness among physicians can increase the 
diagnosis of Behcet's Disease and reduce morbidity.
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